Welcome to our dedicated page for IMGO news (Ticker: IMGO), a resource for investors and traders seeking the latest updates and insights on IMGO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMGO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMGO's position in the market.
Imago BioSciences (IMGO) released positive results from Phase 2 studies of Bomedemstat in Essential Thrombocythemia (ET) and Advanced Myelofibrosis (MF) at the EHA meeting 2022. In ET, 94% of patients had normalized platelets without new thromboembolic events. In MF, 52% of patients showed reduced mutant allele frequencies. The company completed enrollment for the Phase 2 ET study with 73 patients and initiated the first study of Bomedemstat combined with Atezolizumab for small cell lung cancer. Financially, they reported a net loss of $13.7 million for Q2 2022.
Imago BioSciences, a clinical-stage biopharmaceutical company focused on treatments for myeloproliferative neoplasms, will participate in a Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 PM ET. CEO Hugh Young Rienhoff, Jr., MD, will represent the company during this analyst-led session.
The live webcast can be accessed on the company's Investor Relations website, with a replay available for 90 days post-event. Imago is currently evaluating its lead product candidate, Bomedemstat, in two Phase 2 clinical trials.
Imago BioSciences presented positive data from the Phase 2 study of bomedemstat for essential thrombocythemia (ET) at the EHA Congress. Enrollment was completed with 73 patients in April 2022. As of April 29, 2022, 81% of patients achieved normalized platelet counts for at least 12 weeks, with 58% showing symptomatic improvement. No significant safety signals were identified. The company anticipates an End-of-Phase 2 meeting with the FDA in the second half of 2022, aiming for a Phase 3 registrational trial.
Imago BioSciences (IMGO) released positive data from their Phase 2 study on bomedemstat for advanced myelofibrosis (MF). As of April 29, 2022, the findings include: 52% of patients reduced mutant allele frequencies, 85% showed improved or stable fibrosis scores, and 90% of transfusion-independent patients had stable or improved hemoglobin. Bomedemstat has a favorable safety profile, with dysgeusia as the most common side effect. The company plans to evaluate bomedemstat in combination with ruxolitinib and continue patient treatment in an extension study.
Imago BioSciences announced a virtual investor event on June 11, following its presentations at the 2022 European Hematology Association (EHA) Congress on June 10. The event will showcase updated data from two Phase 2 studies of bomedemstat for treating Essential Thrombocythemia and Myelofibrosis. Interested parties can join via phone or webcast. The company has received multiple designations for bomedemstat from the FDA and EMA, indicating its potential significance in treating these blood disorders.
Imago BioSciences (Nasdaq: IMGO) announced participation in three investor conferences featuring CEO Dr. Hugh Young Rienhoff, Jr. The events are:
- HC Wainwright Global Investment Conference: Virtual presentation on May 24, 2022, 7:00 am ET.
- Cowen Oncology Innovation Summit: Analyst-led fireside chat on June 2, 2022, 3:00 pm ET.
- Jefferies Healthcare Conference: Presentation on June 8, 2022, 9:30 am ET.
Live webcasts accessible via the company's Investor Relations page. Imago focuses on novel treatments for myeloproliferative neoplasms, with its lead candidate Bomedemstat under evaluation in Phase 2 trials.
Imago BioSciences (Nasdaq: IMGO) has completed a Type C meeting with the FDA regarding the design of its Phase 3 trial for bomedemstat in essential thrombocythemia (ET). Enrollment for the Phase 2 trial has concluded with 73 patients. The company plans to present additional data at the European Hematology Association Congress. Financially, Imago holds $205.8 million in cash with R&D expenses increasing to $12.5 million, resulting in a net loss of $16.4 million for Q1 2022, compared to $7.1 million the year before.
Imago BioSciences (Nasdaq: IMGO) announced that updated Phase 2 data for its clinical programs involving bomedemstat (IMG-7289) will be presented at the 27th Congress of the European Hematology Association scheduled for June 9-12, 2022. The presentations include a study on advanced myelofibrosis and essential thrombocythemia, both critical conditions treated with bomedemstat. The focus of this investigational drug is its potential as a disease-modifying therapy in these myeloproliferative neoplasms.
Imago BioSciences (Nasdaq: IMGO) has commenced a Phase 1/2 study of bomedemstat in combination with atezolizumab for newly diagnosed extensive stage small cell lung cancer (ES-SCLC), with the first participant treated in Seattle. The study aims to evaluate safety and tolerability in approximately 34 patients. Bomedemstat is a lysine-specific demethylase 1 (LSD1) inhibitor, while atezolizumab is an FDA-approved anti-PD-L1 monoclonal antibody. The study's findings may enhance long-term disease management for ES-SCLC patients.
Imago BioSciences has completed enrollment for its Phase 2 clinical study of bomedemstat in patients with essential thrombocythemia (ET), reaching 73 participants, surpassing the target of 60. This study aims to assess the drug's safety and efficacy in patients who have not responded to standard treatments. Interim data will be presented at the June EHA meeting, with full results expected later this year. Furthermore, an end-of-Phase 2 meeting with the FDA is planned for the second half of 2022 to discuss Phase 3 study preparations.
FAQ
What is the market cap of IMGO (IMGO)?
